Ninlaro, also known by its drug name ixazomib, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma in individuals who have previously tried at least one other therapy. Here are some key points about Ninlaro:

- **Drug Class**: Ninlaro is a proteasome ... read more

Ninlaro, also known by its drug name ixazomib, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma in individuals who have previously tried at least one other therapy. Here are some key points about Ninlaro:

- **Drug Class**: Ninlaro is a proteasome inhibitor, which works by interfering with cell division, specifically targeting cancer cells.
- **Administration**: It is taken orally in the form of a capsule on days 1, 8, and 15 of a 28-day cycle.
- **Combination Therapy**: It is often used in combination with a corticosteroid and Revlimid (lenalidomide) to enhance its effectiveness against myeloma.
- **Common Side Effects**: These include diarrhea, constipation, limb numbness and tingling, nausea, swelling, vomiting, and back pain.
- **Serious Side Effects**: Rare but serious side effects include liver damage, fetal harm in pregnant women, severe skin reactions, and severe gastrointestinal effects.

For individuals dealing with myeloma, Ninlaro offers a treatment option that can be part of a combination therapy approach, providing a regimen that can be administered at home due to its oral dosage form.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Ninlaro (Ixazomib) for Myeloma | MyMyelomaTeam

Refractory Myeloma: 6 Treatment Options | MyMyelomaTeam